+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-03-29Number of Pages: 74

Substance Abuse Treatment Market (Abuse Type - Alcohol Dependence, Tobacco/Nicotine Addiction, and Opioid Addiction; Treatment Type - Alcohol Addiction Treatment (Disulfiram, Acamprosate, and Naltrexone), Tobacco/Nicotine Addiction Treatment (Nicotine Replacement Treatment and Non-nicotine Medication), Drug Abuse Treatment (Methadone, Buprenorphine, and Naltrexone); End User - Outpatient Treatment Centers, Residential Treatment Centers, and Inpatient Treatment Centers) - U.S. Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

U.S. Substance Abuse Treatment Market: Snapshot 

In the U.S. Substance abuse has become a major cause of concern. People in this country are increasingly getting addicted to a variety of drugs, affecting their health and their family life to a large extent. With prolonged drug and alcohol abuse, the prevalence of mental illness and various chronic diseases, such as diabetes and cardiovascular disorders, have increased substantially among consumers, creating a high economic burden on the nation. To control this situation, the U.S. government is focusing on adopting the early intervention as well as prevention strategies, which is expected to drive significant demand for substance abuse treatments, reflecting impressively on the U.S. substance abuse treatment market. 

Currently, all medications used in the treatments of people struggling with substance abuse have been thoroughly examined by the FDA and found to be highly efficient when used properly, under the direction of the prescribing physician. The market is also anticipated to gain remarkably from this in the near future. In 2015, the market was worth US$4.42 bn. Estimated to expand at a CAGR of 12.40% between 2016 and 2024 and reach a value of US$12.43 bn by the end of 2024. 

us substance abuse treatment market

Drug Abuse Treatment Dominates U.S. Substance Abuse Treatment Market 

Alcohol dependence, tobacco/nicotine addiction, and opioid addiction are the main types of substance addiction, a number of U.S. citizens have fallen prey to. With around 15% of the overall population in the U.S. addicted to smoking, the tobacco/nicotine addiction takes the lead among the types of substance abuse taking place in the U.S. 

The key treatments for substance abuse, applied in the U.S., are alcohol addiction treatment, tobacco or Nicotine addiction treatment and drug abuse treatment. Drug abuse treatment reports a higher demand from end users than other substance abuse treatments. Analysts expect this scenario to remain same over the next few years. Methadone, buprenorphine, and naltrexone are the main types of drug abuse treatments utilized in this country. Product innovation in buprenorphine pills and film, and the recent launch of buprenorphine implants is likely to boost the drug abuse treatment segment remarkably in the near future. 

Disulfiram, acamprosate, and naltrexone are the most widely preferred drugs for the treatment of patients struggling with alcohol addiction. Acamprosate is expected to account for the most prominent share among these drugs over the forthcoming years. Nicotine replacement treatment and non-nicotine medications have emerged as the most effective treatments for tobacco or nicotine addiction. 

Thanks to Increasing Popularity of Outpatient Rehab, Outpatient Treatment Centers to Remain Lead among End Users

Outpatient treatment centers, residential treatment centers, and inpatient treatment centers have surfaced as the key end users of the substance abuse treatment in the U.S. Among these, the demand for these treatments is higher in outpatient treatment centers and is anticipated to remain so over the coming years, thanks to the rising popularity of outpatient rehab across the country. 

The U.S. substance abuse treatment market is highly fragmented with a large number of companies operating in it. The prominent ones in them are Mallinckrodt, Purdue Pharma L.P., Sanofi, Dr. Reddy’s Laboratories Ltd., Pfizer Inc., GlaxoSmithKline Plc, Cipla Ltd., Allergan Plc, and Alkermes.

U.S. Substance Abuse Treatment Market: Overview 

This report on substance abuse treatment, studies the current as well as future prospects of the market across the U.S. Substance abuse refers to the harmful or hazardous use of psychoactive substances, including illicit drugs and alcohol. Excessive use of  psychoactive substance can lead to dependence syndrome, that include a strong desire to take drug, difficulties in controlling its use, increased tolerance and sometimes a physical withdrawal state. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered within the scope of the study. This section also provides the overall information and data analysis of the U.S. substance abuse treatment market with respect to the leading market segments based on abuse type, treatment type, end-users, and region. 

The report is a combination of primary and secondary research. Primary research formed the bulk of our research efforts, with information collected from telephonic interviews and interactions via e-mail. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various national and international databases. The report provides market size in terms of US$ Mn for each segment for the period from 2016 to 2024, considering the macro and micro-environmental factors. Growth rates for each segment within the substance abuse treatment market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, expenditure, and regulatory requirements. 

The market overview section of the report includes qualitative analysis of the overall substance abuse treatment market including the determining factors and market dynamics such as drivers, restraints, market trends and opportunities, along with white space analysis. In addition, market attractiveness analysis by country, isotopic application and end-user along with competitive landscape by key players have been provided which explain the intensity of competition in the market considering different geographical locations. The competitive scenario between market players has been evaluated through market share analysis. These factors would help the market players take strategic decisions in order to strengthen their positions and increase their shares in the global market. 

U.S. Substance Abuse Treatment Market: Segmentation 

The U.S. substance abuse treatment market has been studied based on abuse type, treatment type, and end-users segments. In terms of abuse type, substance abuse treatment market is segmented into alcohol dependence, tobacco/nicotine addiction, and opioid addiction. On the basis of treatment type, substance abuse treatment market is further segmented into alcohol addiction treatment, tobacco or Nicotine addiction treatment and drug abuse treatment. Alcohol addiction treatment is further bifurcated into widely preferred drugs, which includes Disulfiram, Acamprosate and Naltrexone. Tobacco or Nicotine addiction treatment segment is further divided into Nicotine Replacement Treatment and Non-Nicotine Medications. 

Nicotine Patch, Nicotine Gum, Nicotine Lozenge, Nicotine Spray, Nicotine Inhaler are the OTCs preferred by addicted considered under Nicotine Replacement Treatment sub-segment. While, Bupropion and Varenicline are the medications used to treat nicotine addiction comes under Non-Nicotine Medications sub-segment. Drug abuse treatment segment is further divided into Methadone, Buprenorphine, and Naltrexone. End-user segment of substance abuse treatment market is divided into outpatient treatment centers, residential treatment centers, and inpatient treatment centers. Outpatient treatment centers is expected to be the most lucrative end-user segment and anticipated to expand at highest CAGR during the forecast period. 

The market for these segments has been extensively analyzed based on their utility, effectiveness, sales, and geographic presence. Market revenue in terms of US$ Mn for the period from 2014 to 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all segments, considering 2015 as the base year. 

U.S. Substance Abuse Treatment Market: Competitive Analysis 

A list of recommendations has been provided for new entrants as well as existing market players to help them establish a strong presence in the market and increase their share. The report also profiles major players of the substance abuse treatment market on the basis of various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Some of the major players profiled in this report include Alkermes, Allergan plc, Cipla Ltd, GlaxoSmithKline plc, Pfizer, Inc., Dr. Reddy’s Laboratories Ltd., Sanofi, Purdue Pharma L.P., Mallinckrodt. 

The U.S. substance abuse treatment market is segmented as follows: 

By Abuse Type

  • Alcohol Dependence
  • Tobacco/Nicotine Addiction
  • Opioid Addiction 

By Treatment

  • Alcohol Addiction Treatment
    • Disulfiram
    • Acamprosate
    • Naltrexone
  • Tobacco/Nicotine Addiction Treatment
  • Nicotine Replacement Treatment
    • Nicotine Patch
    • Nicotine Gum
    • Nicotine Lozenge
    • Nicotine Spray
    • Nicotine Inhaler
  • Non-Nicotine Medication
    • Bupropion
    • Varenicline
  • Drug Abuse Treatment
    • Methadone
    • Buprenorphine
    • Naltrexone 

By End User

  • Outpatient Treatment Centers
  • Residential Treatment Centers
  • Inpatient Treatment Centers 

By Geography

  • The U.S.


 
 
Back To Top